SIADH and Hyponatraemia

A 68-year-old man with known lung cancer is found to have a sodium of 121 mmol/L, a low plasma osmolality of 252 mOsm/kg and a high urine osmolality of 350 mOsm/kg. He is clinically euvolaemic, takes no diuretics and has a urine sodium of 45 mmol/L.

What is the likely cause?

SIADH, syndrome of inappropriate ADH secretion, driven by his lung cancer. Small-cell carcinoma is the classic cause.

How would you initially manage this patient?

My priority is to assess how symptomatic he is. Given his sodium of 121 mmol/L, I would arrange urgent hospital-based assessment and monitoring. I would perform an A to E assessment following the CCrISP protocol with a full set of observations, looking for seizures, vomiting, reduced consciousness and cardiorespiratory distress.

I would assess his volume status, confirming euvolaemia, and confirm the sodium on a formal laboratory sample rather than a gas alone. I would exclude adrenal insufficiency, hypothyroidism and renal impairment before confirming SIADH.

I would initiate fluid restriction, typically 800–1,000 mL per day, and monitor his serum sodium approximately six-hourly initially, alongside strict fluid balance and urine output.

I would stop any contributing drugs and liaise with the oncology team regarding management of his underlying malignancy.

If fluid restriction fails, I would seek specialist advice regarding second-line treatment, such as oral urea or tolvaptan.

If he develops severe neurological symptoms, I would involve critical care urgently, alongside senior and biochemistry input. I would administer 150 mL of 3% hypertonic saline over 20 minutes, recheck his sodium and neurological status, and repeat if necessary, aiming for an initial sodium rise of approximately 5 mmol/L.

I would aim to limit sodium correction to no more than 8 mmol/L in any 24 hours to minimise the risk of osmotic demyelination, with particular caution in chronic hyponatraemia.

πŸ‘©β€βš•οΈ Tolvaptan is started under specialist supervision and without concurrent fluid restriction, because the sodium can then rise too fast. Demeclocycline is generally not recommended in current European guidance because of its potential nephrotoxicity.

What are the diagnostic criteria for SIADH?

  • Serum sodium < 135 mmol/L
  • Plasma osmolality < 275 mOsm/kg
  • Urine osmolality > 100 mOsm/kg
  • Urine sodium > 30 mmol/L on a normal salt intake
  • Clinically euvolaemic, off diuretics, with normal thyroid and adrenal function

Why do you check plasma osmolality in hyponatraemia?

To confirm the hyponatraemia is genuine and hypotonic, with a plasma osmolality below 275 mOsm/kg.

It excludes pseudohyponatraemia, a laboratory artefact of severe hyperlipidaemia or hyperproteinaemia where measured osmolality is normal.

It also excludes translocational hyponatraemia, where an osmotically active solute such as glucose or mannitol pulls water into the plasma, so osmolality is normal or high.

What are the different causes of true hypo-osmolar hyponatraemia?

  • Hypovolaemic with renal losses (urine sodium > 30 mmol/L):

Diuretics, especially thiazides, Addison's disease, salt-wasting nephropathy, cerebral salt wasting, osmotic diuresis.

  • Hypovolaemic with extra-renal losses (urine sodium < 30 mmol/L):

Vomiting, diarrhoea, sweating, burns, third-space losses in pancreatitis or bowel obstruction.

  • Euvolaemic:

SIADH, severe hypothyroidism, glucocorticoid deficiency from secondary adrenal insufficiency, primary polydipsia, low solute intake such as a tea and toast diet or beer potomania.

  • Hypervolaemic:

Congestive cardiac failure, liver cirrhosis, nephrotic syndrome, advanced CKD and AKI.

πŸ‘©β€βš•οΈ In hypovolaemic and hypervolaemic states circulating volume is low, or perceived as low, so ADH is released despite the low sodium. Hypothyroidism causes hyponatraemia in its own right, not through SIADH, and usually only when severe.

What are the different causes of SIADH?

  • Central nervous system: Subarachnoid haemorrhage, head injury, meningitis, cerebral abscess, stroke
  • Pulmonary: Pneumonia, tuberculosis, lung abscess, positive pressure ventilation
  • Malignancy: Small-cell lung cancer classically, also pancreatic and prostatic
  • Drugs: Carbamazepine, SSRIs, tricyclics such as amitriptyline, cyclophosphamide, opioids
  • Surgical: Post-operative pain, nausea and the stress response

What is the safe rate of sodium correction?

  • No more than 10 mmol/L in the first 24 hours
  • No more than 8 mmol/L in any 24 hours after that, so no more than 18 mmol/L by 48 hours
  • A tighter ceiling of 8 mmol/L in the first 24 hours in high risk patients: Malnutrition, alcohol excess, liver disease, hypokalaemia or a sodium below 105 mmol/L

The exception is seizures or a falling conscious level, where a deliberate rise of 5 mmol/L in the first hour with hypertonic saline is correct.

πŸ‘©β€βš•οΈ That rapid initial rise still counts towards the 10 mmol/L allowed in the first 24 hours.

Why does the rate of sodium correction have to be controlled and slow?

In chronic hyponatraemia, the brain initially loses electrolytes and subsequently organic osmolytes to reduce intracellular osmolality and prevent cerebral oedema. Reaccumulation of these osmolytes takes several days.

If serum sodium is corrected too rapidly, extracellular osmolality rises before brain cells can readapt. Water moves out of neurons and glial cells, causing cellular dehydration and potentially osmotic demyelination syndrome (ODS).

Neurological deterioration is typically delayed by 2–6 days and may cause dysarthria, dysphagia, quadriparesis or locked-in syndrome. It can result in permanent neurological disability or death.

Where is ADH secreted?

ADH, also called vasopressin, is synthesised in the supraoptic and paraventricular nuclei of the hypothalamus. It travels down the axons of the hypothalamo-hypophyseal tract to the posterior pituitary, where it is stored until release.

πŸ‘©β€βš•οΈ The posterior pituitary is neural tissue, so it stores the hormone rather than making it.

What stimulates the release of ADH?

  • Increased plasma osmolality of 1 to 2%, detected by hypothalamic osmoreceptors

Reduced...

  • Circulating volume, detected by low-pressure cardiopulmonary stretch receptors, primarily located in the atria and pulmonary vessels
  • Arterial blood pressure, detected by baroreceptors in the carotid sinus and aortic arch

Both signals reach the hypothalamus via afferent pathways involving the vagus CN X and, for the carotid sinus, the glossopharyngeal CN IX.

  • Angiotensin II
  • Nausea and vomiting
  • Pain, surgery and the stress response
  • Hypoxia
  • Morphine, nicotine and cyclophosphamide

πŸ‘©β€βš•οΈ Volume overrides osmolality. A hypovolaemic patient keeps secreting ADH even when the plasma is already dilute, which is how hypovolaemia causes hyponatraemia. Alcohol suppresses ADH release.

What is the half-life of ADH?

15 to 20 minutes.

What are the actions of ADH?

ADH binds to V2 receptors on the basolateral membrane of principal cells in the late distal tubule and collecting duct, activating cyclic AMP signalling and promoting the insertion of aquaporin-2 water channels into the apical membrane. Water is reabsorbed down the medullary osmotic gradient, reducing urine volume, increasing urine osmolality and lowering plasma osmolality.

ADH also stimulates NKCC2 activity in the thick ascending limb and increases urea permeability in the inner medullary collecting duct, helping maintain the medullary osmotic gradient.

V1a receptors on vascular smooth muscle cause vasoconstriction, increasing systemic vascular resistance and supporting blood pressure, particularly at high ADH concentrations during shock. V1b receptors in the anterior pituitary stimulate ACTH release.

πŸ‘©β€βš•οΈ Tolvaptan selectively blocks V2 receptors, promoting the excretion of electrolyte-free water (aquaresis), which raises serum sodium in SIADH.

What is the difference between cranial and nephrogenic diabetes insipidus?

In cranial diabetes insipidus, now called arginine vasopressin deficiency, ADH secretion from the posterior pituitary is impaired. In nephrogenic diabetes insipidus, now called arginine vasopressin resistance, ADH is secreted normally but the collecting duct does not respond.

πŸ‘©β€βš•οΈ The renaming was agreed in 2022 to stop confusion with diabetes mellitus. Both sets of names are in current use.

How does a water deprivation test separate cranial from nephrogenic diabetes insipidus?

Fluid is withheld and plasma and urine osmolality are measured hourly, then desmopressin is given and urine osmolality is measured again. Deprivation stops when plasma osmolality exceeds 295 to 300 mOsm/kg, plasma sodium exceeds 145 mmol/L, or urine osmolality plateaus while plasma osmolality is still rising. It also stops for excessive weight loss or symptoms, and it is done under specialist supervision.

After desmopressin, urine osmolality rises by more than 100% in complete arginine vasopressin deficiency and by up to 50% in partial deficiency. In arginine vasopressin resistance it barely moves in partial resistance, and does not rise at all in complete resistance.

πŸ‘©β€βš•οΈ A urine osmolality below 300 mOsm/kg is hypotonic. A normal concentrating response reaches over 800 mOsm/kg. Partial deficiency and partial resistance overlap, so a borderline result needs specialist interpretation.

Subscribe to MRCS28

Don’t miss out on the latest issues. Sign up now to get access to the library of members-only issues.
jamie@example.com
Subscribe